Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ROXI-CAT-I
NCT07410117Phase 3Recruiting
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Mar 2026
- Primary completion
- Jan 2030
- Modality
- Monoclonal Antibodies
- Countries
- 3
01
Overview
A Phase 3 trial of REGN7508 in cancer-associated thrombosis (CAT), sponsored by Regeneron Pharmaceuticals. Started Mar 2026; status: recruiting.
02
Drugs
REGN7508
03
Conditions
cancer-associated thrombosis (CAT)
Beyond the preview
Go deeper on NCT07410117.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07410117.